| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
2,6-Dichloro-4-iodopyridine does not have a defined pharmacological target of its own, as it is a synthetic intermediate. As a halogenated pyridine, it serves as a key building block for the synthesis of various biologically active compounds. The different halogen atoms (chlorine and iodine) provide orthogonal handles for selective functionalization in medicinal chemistry.
|
|---|---|
| ln Vitro |
In vitro, 2,6-dichloro-4-iodopyridine is primarily used as a chemical reagent and synthetic intermediate. As a halogenated pyridine, it is a common building block for the construction of drug-like molecules through selective cross-coupling reactions. The iodine atom at the 4-position is more reactive than the chlorine atoms, enabling sequential functionalization. The compound is widely utilized in pharmaceutical and agrochemical research.
|
| ln Vivo |
In vivo activity data for 2,6-dichloro-4-iodopyridine itself are not available, as the compound is not intended for direct in vivo administration. Rather, it is a precursor used in the synthesis of drug candidates that are subsequently evaluated in animal models. The compound's in vivo relevance is indirect, through the biological activities of the final pharmaceutical compounds derived from its halogenated pyridine scaffold.
|
| Enzyme Assay |
For in vitro chemical synthesis, 2,6-dichloro-4-iodopyridine is used as a building block for the preparation of various compounds. The iodine atom at the 4-position provides a handle for selective cross-coupling reactions such as Suzuki-Miyaura couplings, while the chlorine atoms at the 2- and 6-positions can be used for subsequent nucleophilic aromatic substitution reactions. Standard protocols involve reacting the compound with appropriate reagents under controlled conditions, such as using palladium catalysts for selective coupling at the iodine site.
|
| Cell Assay |
For in vitro cell-based experiments, 2,6-dichloro-4-iodopyridine is used as an intermediate in the synthesis of compounds that are tested in cell viability, proliferation, and cytotoxicity assays. The compound itself is not typically evaluated in cell-based assays. Standard cell culture protocols for test compounds synthesized from this intermediate involve dissolving the final product in DMSO and diluting to working concentrations in appropriate cell culture medium.
|
| Animal Protocol |
In vivo animal studies using 2,6-dichloro-4-iodopyridine are conducted on the final drug compounds synthesized from it, not on the intermediate itself. For pharmaceutical candidates derived from this building block, efficacy studies would typically be performed in mouse models of the relevant disease. Standard in vivo protocols involve administration to rodents via oral gavage or intraperitoneal injection, with appropriate pharmacokinetic and pharmacodynamic endpoints.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of 2,6-dichloro-4-iodopyridine as a standalone compound are not characterized in the literature. The compound has a molecular weight of 273.89 g/mol, which is within the favorable range for oral bioavailability. The halogen atoms may influence metabolic stability and lipophilicity. The iodine atom may be subject to oxidative deiodination. Empirical pharmacokinetic data are not available for this intermediate compound.
|
| Toxicity/Toxicokinetics |
2,6-Dichloro-4-iodopyridine is a research chemical and should be handled with appropriate laboratory safety precautions. As a halogenated compound, it may cause skin and eye irritation. The compound should be stored under appropriate conditions. It is for research use only and not for human therapeutic or diagnostic applications. Specific LD₅₀ values, acute toxicity classifications, and chronic toxicity data are not available in the public literature.
|
| Additional Infomation |
2,6-Dichloro-4-iodopyridine (CAS 98027-84-0) is primarily a research-grade chemical intermediate, not an FDA-approved pharmaceutical drug. Its primary applications are as a building block for pharmaceutical and agrochemical research and as a biochemical reagent for biomedical research. No clinical trials or approved therapeutic indications exist for this compound.
|
| Molecular Formula |
C5H2CL2IN
|
|---|---|
| Molecular Weight |
273.89
|
| Exact Mass |
272.86
|
| CAS # |
98027-84-0
|
| PubChem CID |
11737393
|
| Appearance |
White to off-white solid powder
|
| Density |
2.1±0.1 g/cm3
|
| Boiling Point |
291.6±35.0 °C at 760 mmHg
|
| Melting Point |
161-165ºC
|
| Flash Point |
130.1±25.9 °C
|
| Vapour Pressure |
0.0±0.6 mmHg at 25°C
|
| Index of Refraction |
1.652
|
| LogP |
2.1
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
1
|
| Rotatable Bond Count |
0
|
| Heavy Atom Count |
9
|
| Complexity |
91
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
IC1C=C(N=C(C=1)Cl)Cl
|
| InChi Key |
NGSKFMPSBUAUNE-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C5H2Cl2IN/c6-4-1-3(8)2-5(7)9-4/h1-2H
|
| Chemical Name |
2,6-dichloro-4-iodopyridine
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: (1). This product requires protection from light (avoid light exposure) during transportation and storage. (2). This product is not stable in solution, please use freshly prepared working solution for optimal results. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: ~33.3 mg/mL (~121.7 mM; with ultrasonication and warming by heating to 60°C)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (9.13 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), Clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (25.0 mg/mL) to 900 μL of corn oil and mix well. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.6511 mL | 18.2555 mL | 36.5110 mL | |
| 5 mM | 0.7302 mL | 3.6511 mL | 7.3022 mL | |
| 10 mM | 0.3651 mL | 1.8256 mL | 3.6511 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
